Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis

• Published in: Clinical gastroenterology and hepatology Vol. 19; no. 11; pp. 2274 - 2283.e5
• Main Authors: Stine, Jonathan G., Munaganuru, Nagambika, Barnard, Abbey, Wang, Jennifer L., Kaulback, Kellee, Argo, Curtis K., Singh, Siddarth, Fowler, Kathryn J., Sirlin, Claude B., Loomba, Rohit
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2021
• Subjects: Adult; Biomarkers; Clinical Trial; Female; Gastroenterology and Hepatology; Histology; Humans; Liver; Liver Biopsy; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease - diagnostic imaging; Protons; Steatohepatitis; Steatosis; NAS; FDA; NAFLD; OR; Clinical Trial; Liver Biopsy; MRI; CI; Histology; NASH; Steatosis; PDFF; Steatohepatitis; magnetic resonance imaging; odds ratio; proton density fat fraction; NAFLD Activity Score; nonalcoholic steatohepatitis; nonalcoholic fatty liver disease; confidence interval; Food and Drug Administration

Magnetic resonance imaging proton density fat fraction (MRI-PDFF) offers promise as a non-invasive biomarker of treatment response in early-phase nonalcoholic steatohepatitis (NASH) trials. We performed a systematic review to quantify the association between a ≥ 30% reduction in MRI-PDFF and histolo...